Slow Bull
The market, slowly. FRIDAY, 25 SEPTEMBER 2026

GT Biopharma, Inc.

GTBP Nasdaq SEC CIK 109657
Follow GT Biopharma Weekly email: filings, results, news

Financials

Reported figures only · latest: Q2 2026 USD · US GAAP
Net income −$4.5M +85% vs same quarter last year
EPS, diluted −$0.12 +98.9% vs same quarter last year
Operating cash flow −$4.3M −41.3% vs same quarter last year
Operating income −$4.5M −198.2% vs same quarter last year
Net income by quarter
−$3.4M
−$3.8M
−$776K
−$30.2M
$8.3M
−$5.7M
−$2.8M
−$4.5M
Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$300M−$200M−$100M$0$100MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25-−$28.4M
FY24-−$13.2M
FY23-−$7.6M
FY22-−$20.9M
FY21-−$58M
FY20$0−$28.3M
FY19$0−$38.6M
FY18-−$259.2M
FY17$0−$144.2M
FY16$0$9.8M
FY15$27K−$21.5M
FY14$61K−$23.5M
FY13$368K−$501K
FY12$342K−$5.2M
FY11$26K−$3.7M
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−80000%−60000%−40000%−20000%0%20000%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearGross marginOperating marginNet margin
FY25---
FY24---
FY23---
FY22---
FY21---
FY20---
FY19---
FY18---
FY17---
FY16---
FY15100%−33063%−79485.2%
FY146.6%−3927.9%−38506.6%
FY1338.6%−215.5%−136.1%
FY1272.5%−1027.5%−1512%
FY11−84.6%−15107.7%−14230.8%
Free cash flowOperating cash flow minus capital expenditure
−$15M−$10M−$5M$0FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25-
FY24-
FY23-
FY22-
FY21-
FY20-
FY19−$3.7M
FY18−$10.7M
FY17−$5.4M
FY16−$1.9M
FY15−$4.7M
FY14−$1.8M
FY13−$442K
FY12−$989K
FY11−$963K
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • GT Biopharma
  • Healthcare median
−80000%−60000%−40000%−20000%0%20000%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearGT BiopharmaHealthcare median
FY25-9.8%
FY24-10.5%
FY23-5.3%
FY22-12.7%
FY21-10.8%
FY20--
FY19--
FY18--
FY17--
FY16--
FY15−79485.2%-
FY14−38506.6%-
FY13−136.1%-
FY12−1512%-
FY11−14230.8%-

News

No stories filed under GT Biopharma yet - coverage appears here as the news feed clusters it.